TRIB Jun 2024 2.500 put
| Previous Close | 1.0000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 2.4500 |
| Strike | 2.50 |
| Expire Date | 2024-06-21 |
| Day's Range | 1.0000 - 1.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
GlobeNewswireTrinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025- -Strong sequential 39% Q/Q growth on Point-of-Care revenues associated with successful rollout and scaling of HIV test production- -Disciplined execution of operational efficiencies led to 3.6 percentage point Q/Q increase in gross margin percentage with further improvements expected through 2024 and into early 2025- DUBLIN, Ireland,
- GlobeNewswire
Trinity Biotech plc to Announce Q1 2024 Financial Results
Conference Call Scheduled for Thursday, May 23, 2024 at 8:30 AM ET.DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET. Conference Call Dial-In & Webcast Information Date:Thursday, May 23, 2024Time:8:30 AM ETUnited St
- GlobeNewswire
Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI
DUBLIN, Ireland, May 16, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with medical artificial intelligence (“AI”) company PulseAI to enhance the Company’s recently acquired continuous glucose monitor (CGM) biosensor technology. Under this collaboration, Trinity Biotech will provide a pool of unique multi-p
